These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11928716)

  • 1. Novel mutations in C-terminal channel region of the ryanodine receptor in malignant hyperthermia patients.
    Oyamada H; Oguchi K; Saitoh N; Yamazawa T; Hirose K; Kawana Y; Wakatsuki K; Oguchi K; Tagami M; Hanaoka K; Endo M; Iino M
    Jpn J Pharmacol; 2002 Feb; 88(2):159-66. PubMed ID: 11928716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced threshold for store overload-induced Ca
    Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW
    Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant hyperthermia susceptibility diagnosed with a family-specific ryanodine receptor gene type 1 mutation.
    Tanabe T; Fukusaki M; Terao Y; Yamashita K; Sumikawa K; Mukaida K; Ibarra CA; Nishino I
    J Anesth; 2008; 22(1):70-3. PubMed ID: 18306019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region.
    Murayama T; Kurebayashi N; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    PLoS One; 2015; 10(6):e0130606. PubMed ID: 26115329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.
    Murayama T; Kurebayashi N; Ogawa H; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    Hum Mutat; 2016 Nov; 37(11):1231-1241. PubMed ID: 27586648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.
    Eltit JM; Bannister RA; Moua O; Altamirano F; Hopkins PM; Pessah IN; Molinski TF; López JR; Beam KG; Allen PD
    Proc Natl Acad Sci U S A; 2012 May; 109(20):7923-8. PubMed ID: 22547813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia.
    Galli L; Orrico A; Lorenzini S; Censini S; Falciani M; Covacci A; Tegazzin V; Sorrentino V
    Hum Mutat; 2006 Aug; 27(8):830. PubMed ID: 16835904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing the number of diagnostic mutations in malignant hyperthermia.
    Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
    Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis.
    Tilgen N; Zorzato F; Halliger-Keller B; Muntoni F; Sewry C; Palmucci LM; Schneider C; Hauser E; Lehmann-Horn F; Müller CR; Treves S
    Hum Mol Genet; 2001 Dec; 10(25):2879-87. PubMed ID: 11741831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant hyperthermia-associated mutations in the S2-S3 cytoplasmic loop of type 1 ryanodine receptor calcium channel impair calcium-dependent inactivation.
    Gomez AC; Holford TW; Yamaguchi N
    Am J Physiol Cell Physiol; 2016 Nov; 311(5):C749-C757. PubMed ID: 27558158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).
    Ta TA; Pessah IN
    Neurotoxicology; 2007 Jul; 28(4):770-9. PubMed ID: 17023049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia families.
    Tammaro A; Di Martino A; Bracco A; Cozzolino S; Savoia G; Andria B; Cannavo A; Spagnuolo M; Piluso G; Aurino S; Nigro V
    Clin Genet; 2011 May; 79(5):438-47. PubMed ID: 20681998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel skeletal muscle ryanodine receptor mutation in a large Brazilian family with malignant hyperthermia.
    McWilliams S; Nelson T; Sudo RT; Zapata-Sudo G; Batti M; Sambuughin N
    Clin Genet; 2002 Jul; 62(1):80-3. PubMed ID: 12123492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular genetic analysis of the ryanodine receptor gene (RYR1) in Korean malignant hyperthermia families].
    Lee H; Kim DC; Lee JH; Cho YG; Lee HS; Choi SI; Kim DS
    Korean J Lab Med; 2010 Dec; 30(6):702-10. PubMed ID: 21157159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population.
    Sambuughin N; Holley H; Muldoon S; Brandom BW; de Bantel AM; Tobin JR; Nelson TE; Goldfarb LG
    Anesthesiology; 2005 Mar; 102(3):515-21. PubMed ID: 15731587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. North American malignant hyperthermia population: screening of the ryanodine receptor gene and identification of novel mutations.
    Sambuughin N; Sei Y; Gallagher KL; Wyre HW; Madsen D; Nelson TE; Fletcher JE; Rosenberg H; Muldoon SM
    Anesthesiology; 2001 Sep; 95(3):594-9. PubMed ID: 11575529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations to Gly2370, Gly2373 or Gly2375 in malignant hyperthermia domain 2 decrease caffeine and cresol sensitivity of the rabbit skeletal-muscle Ca2+-release channel (ryanodine receptor isoform 1).
    Du GG; Oyamada H; Khanna VK; MacLennan DH
    Biochem J; 2001 Nov; 360(Pt 1):97-105. PubMed ID: 11695996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.